These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9201569)

  • 1. Pharmacokinetics of amikacin in intensive care unit patients.
    Fernández de Gatta MM; Mendez ME; Romano S; Calvo MV; Dominguez-Gil A; Lanao JM
    J Clin Pharm Ther; 1996 Dec; 21(6):417-21. PubMed ID: 9201569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
    Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
    De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of once-daily amikacin dose in critically ill adults.
    Šíma M; Hartinger J; Cikánková T; Slanař O
    J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients.
    Debord J; Voultoury JC; Lachatre G; Favereau JP; Gay R
    Int J Biomed Comput; 1994 Jun; 36(1-2):135-7. PubMed ID: 7927853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.
    Panomvana D; Kiatjaroensin SA; Phiboonbanakit D
    Clin Pharmacokinet; 2007; 46(10):859-66. PubMed ID: 17854235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of amikacin in critically ill patients.
    Bressolle F; Gouby A; Martinez JM; Joubert P; Saissi G; Guillaud R; Gomeni R
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1682-9. PubMed ID: 8807062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
    Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT
    Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
    Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
    J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients.
    Romano S; Del Mar Fdez de Gatta M; Calvo V; Mendez E; Domínguez-Gil A; Lanao JM
    Clin Drug Investig; 1998; 15(5):435-44. PubMed ID: 18370499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of once-daily amikacin in healthy foals and therapeutic drug monitoring in hospitalized equine neonates.
    Bucki EP; Giguère S; Macpherson M; Davis R
    J Vet Intern Med; 2004; 18(5):728-33. PubMed ID: 15515591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients.
    Debord J; Voultoury JC; Lachatre G; Gay C; Favereau JP; Gay R
    Eur J Clin Pharmacol; 1992; 43(4):435-6. PubMed ID: 1451727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial.
    De Winter S; Wauters J; Meersseman W; Verhaegen J; Van Wijngaerden E; Peetermans W; Annaert P; Verelst S; Spriet I
    Int J Antimicrob Agents; 2018 Apr; 51(4):562-570. PubMed ID: 29180278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracorporeal membrane oxygenation (ECMO) does not impact on amikacin pharmacokinetics: a case-control study.
    Gélisse E; Neuville M; de Montmollin E; Bouadma L; Mourvillier B; Timsit JF; Sonneville R
    Intensive Care Med; 2016 May; 42(5):946-948. PubMed ID: 27010471
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
    Luyt CE; Eldon MA; Stass H; Gribben D; Corkery K; Chastre J
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):183-90. PubMed ID: 21361783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.